Can weight loss drugs help endometrial cancer patients during chemo?

NCT ID NCT06751589

Recruiting now Symptom relief Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether weight loss drugs like tirzepatide and semaglutide are practical and safe for endometrial cancer patients who are overweight, obese, or have diabetes and are undergoing chemotherapy. About 36 participants will take weekly doses for 24 weeks. Researchers will track how many complete the treatment, side effects, and changes in weight and blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus endometrial cancer endometrium neoplasm Obesity Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.